(151 days)
Not Found
No
The device description and performance studies focus on the mechanical and functional aspects of a sterile, single-use needle for subcutaneous injection, with no mention of AI or ML capabilities.
No.
This device is a needle used for drug delivery, not a device that itself provides a therapeutic effect.
No
The device is a needle intended for subcutaneous injection of drugs, not for diagnosing conditions.
No
The device description clearly describes a physical needle for subcutaneous injection, not a software product.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for the "subcutaneous injection of drugs." This is a delivery mechanism for medication, not a test performed on a sample taken from the body to diagnose a condition or provide information about a physiological state.
- Device Description: The description details a needle for injecting substances under the skin. It does not mention any components or processes related to analyzing biological samples.
- Lack of IVD Characteristics: There is no mention of analyzing blood, urine, tissue, or any other biological specimen. There is no mention of reagents, assays, or diagnostic information being generated.
Therefore, the NovoFine® Plus 32 G 4 mm needle is a medical device for drug delivery, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
Indications for Use: NovoFine® Plus 32 G 4 mm needles are intended for use with pen injector devices for the subcutaneous injection of drugs.
Product codes
FMI
Device Description
NovoFine® Plus 32 G 4 mm needle is a sterile single use needle for subcutaneous injection of drugs with a pen injector device. Prior to giving an injection, the protective tab is removed from the outer needle cap of the single-use disposable needle. With the disposable needle remaining in the outer needle cap, it is then carefully screwed onto the injection delivery device until tight and then the needle outer and inner caps are removed. Use the needles as described in the instructions for use that comes with the pen-injector device and as instructed by the healthcare professional.
After the injection, the needle is removed from the skin. The needle is detached from the injection device and disposed of in accordance with national/local regulations. For each subsequent injection, a new disposable needle must be used.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
subcutaneous
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
The NovoFine® Plus needle will be manufactured in accordance with current Good Manufacturing Practices for Medical Devices. Biocompatibility and performance tests have been performed and the results are in compliance with existing domestic and international standards.
The clarification to the intended use of the subject pen needle device, does not introduce critical differences or new risks to the intended use of the device. The proposed clarification reflects current testing practice and aligns with compatibility summary provided in the submission. As part of the Quality System, NovoFine® Plus has been tested for functional compatibility according to ISO 11608-2:2012 with all leading pen injectors available on the market. This testing has shown connectivity to NovoFine® Plus and maintenance of the dose accuracy through the needle of all leading pen-injectors on the market covering different types of drugs. Thus, subject needle device meets requirements for its intended use and supports the proposed clarification.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 880.5570 Hypodermic single lumen needle.
(a)
Identification. A hypodermic single lumen needle is a device intended to inject fluids into, or withdraw fluids from, parts of the body below the surface of the skin. The device consists of a metal tube that is sharpened at one end and at the other end joined to a female connector (hub) designed to mate with a male connector (nozzle) of a piston syringe or an intravascular administration set.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, with the letters "FDA" in a blue square. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
December 19, 2020
Novo Nordisk Inc. Hiral Shah Associate Manager, Regulatory Affairs P.O Box 846 Plainsboro, New Jersey 08536
Re: K202005
Trade/Device Name: NovoFine Plus 32G Tip x 4 mm Regulation Number: 21 CFR 880.5570 Regulation Name: Hypodermic Single Lumen Needle Regulatory Class: Class II Product Code: FMI Dated: November 23, 2020 Received: November 25, 2020
Dear Hiral Shah:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's
1
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Rumi Young Acting Assistant Director DHT3C: Division of Drug Delivery and General Hospital Devices, and Human Factors OHT3: Office of GastroRenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) NA
Device Name NovoFine® Plus 32 G 4 mm
Indications for Use (Describe)
Indications for Use: NovoFine® Plus 32 G 4 mm needles are intended for use with pen injector devices for the subcutaneous injection of drugs.
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D)
X Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW *
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
CONFIDENTIAL
Date: Version: Status: Page:
18 December 2020 | Novo Nordisk 1.0 Final 1 of 6
Traditional 510(k)
NovoFine® Plus 32G 4 mm needle
Section 5 Summary
Author Regulatory Affairs Novo Nordisk Inc.
4
Table of contents
Page
| Table of contents | |||||
|---|---|---|---|---|---|
| 510(k) Summary | |||||
| 1 Submitter's Name and Address: | |||||
| 2 Name of Device: | |||||
| 3 Substantial Equivalence: | |||||
| 4 Device Description: | |||||
| 5 Intended Use: | |||||
| 6 Technological Characteristics: | |||||
| 6.1 | Non-Clinical Tests Performed: | ||||
| 6.2 | Clinical Tests Performed: | ||||
| 6.3 | Conclusion drawn from the non-clinical and clinical tests: |
5
510(k) Summary
21 CFR 807.87(h)
As required by 21 CFR 807.92(a)
Date Prepared: December 18, 2020
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR 807.92. The NovoFine® Plus 32 G 4 mm needle meets all applicable product and quality standards for hypodermic single lumen needle products.
1 Submitter's Name and Address:
Novo Nordisk Inc. 800 Scudders Mill Road Plainsboro, New Jersey 08536
Contact Person: Hiral Shah Palkhiwala Associate Manager, Regulatory Affairs Tel: 609-787-7603 Email: hpaw@novonrdisk.com
2 Name of Device:
Proprietary Name: Common or usual name: Classification:
Product Code:
NovoFine® Plus 32 G 4 mm Pen Needle Class II device; 21 CFR 880.5570, (hypodermic single lumen needle) FMI (hypodermic single lumen needle)
Substantial Equivalence: 3
Predicate Device: NovoFine® Plus 32 G 4 mm ETW cleared under K133738 on May 21, 2014.
The main purpose of this submission is to provide clarification to the intended use which is similar amongst the cited predicate device.
Additionally, following minor changes have been implemented between the subject device and the predicate NovoFine Plus.
6
a. Tighten specification for minimum inner diameter of the cannula
- b. Change in hub and inner cap polypropylene sub-type
- c. Addition of Contract Manufacturing facility
- d. Addition of packaging configurations (4 needles (trade) and 6 needles (trade and sample))
The above changes do not affect intended use, indications for use, technological characteristics, the general type of materials, principle of operation, shelf life, and biocompatibility. Therefore, NovoFine® Plus that is the subject of this 510(k) is considered substantial equivalent to the NovoFine® Plus cleared on May 21, 2014, 2006 (K133738) the predicate device.
The term "substantial equivalence" as used in this 510(k) notification is limited to the definition of substantial equivalence as found in the Federal Food, Drug, and Cosmetic Act, as amended and as supplied under 21 CFR 807, Subpart E under which a device can be marketed without pre-market approval or reclassification. A determination of substantial equivalency under this notification is not intended to have any bearing whatsoever on the resolution of patent infringement suits or any other patent matters. No statement related to, or in support of substantial equivalence herein shall be construed as an admission against interest under the US Patent laws or their application by the court.
Device Description: ব
NovoFine® Plus 32 G 4 mm needle is a sterile single use needle for subcutaneous injection of drugs with a pen injector device. Prior to giving an injection, the protective tab is removed from the outer needle cap of the single-use disposable needle. With the disposable needle remaining in the outer needle cap, it is then carefully screwed onto the injection delivery device until tight and then the needle outer and inner caps are removed. Use the needles as described in the instructions for use that comes with the pen-injector device and as instructed by the healthcare professional.
After the injection, the needle is removed from the skin. The needle is detached from the injection device and disposed of in accordance with national/local regulations. For each subsequent injection, a new disposable needle must be used.
5 Intended Use:
NovoFine® Plus 32 G 4mm is intended for use with pen injector devices for the subcutaneous injection of drugs.
Comparison with Predicate Devices:
The subject device is considered substantially equivalent in device design, general type of materials, fundamental scientific technology and device performance as the predicate devices (K133738). The purpose of this submission is to provide clarification to the intended use which is similar amongst the cited predicate device. The table below provides a side by side comparison of the subject device compared to its predicate.
7
| Table 1 | Side by side comparison of the subject device and predicate device | |
|---|---|---|
| Features | NovoFine® Plus 32G 4 mm | |
| Subject device | NovoFine® Plus 32G 4 mm | |
| Predicate device | ||
| Parameter | K202005 | K133738 |
| Intended Use | Intended for use with pen injector | |
| devices for the subcutaneous | ||
| injection of drugs | Intended for use with pen injector | |
| devices for the subcutaneous | ||
| injection of drugs, including insulin, | ||
| GLP-1 analogs, and somatropin. | ||
| Product type | Hypodermic single lumen needle | Hypodermic single lumen needle |
| Durability | 5 years from production date | 5 years from production date |
| Biocompatibility | EN ISO 10993-1 | EN ISO 10993-1 |
| Reuse | Single use | Single use |
| Labeling | See Section 13: Proposed Labeling | |
| Labeling configuration: | ||
| 100 needles (trade) | ||
| 7 needles (sample) | ||
| 6 needles (trade and sample) | ||
| 4 needles (trade) | See Section 13: Proposed Labeling | |
| Labeling configuration: | ||
| 100 needles (trade) | ||
| 7 needles (sample) | ||
| Specifications | ||
| Outer diameter, tip | 0.22-0.25 mm | 0.22-0.25 mm |
| Outer diameter, cylindrical | ||
| part | 0.25-0.27 mm | 0.25-0.27 mm |
| Inner diameter | Minimum 0.146 mm | 0.145-0.16 mm |
| Length from hub | 4 mm | 4 mm |
| Gauge | 32G | 32G |
| Tip configuration | 1st and 2nd grinding and glass | |
| blasting | 1st and 2nd grinding and glass | |
| blasting | ||
| Hub/≤needle ≥ bond | ||
| strength | Fmin = 11.2 N | Fmin = 11.2 N |
| Materials | ||
| Hub | Polypropylene (PP) with PE white | |
| master batch | ||
| Color: White | Polypropylene (PP) with PE white | |
| master batch | ||
| Color: White | ||
| Cannula | Stainless steel | |
| AISI / SUS 304 | ||
| DIN-kurzname: X 5 CrNi 18 10* | Stainless steel | |
| AISI / SUS 304 | ||
| DIN-kurzname: X 5 CrNi 18 9 | ||
| Glue | Single component epoxy adhesive | |
| Color: Light yellow | Single component epoxy adhesive | |
| Color: Light yellow | ||
| Inner needle cap | Polypropylene (PP) | |
| Color: Transparent | Polypropylene (PP) | |
| Color: Transparent | ||
| Outer needle cap | Polypropylene (PP) | |
| Color: Transparent white | Polypropylene (PP) | |
| Color: Transparent white | ||
| Materials | ||
| Sealing paper | Medical grade paper for steam | |
| sterilization | Medical grade paper for steam | |
| sterilization | ||
| Lubricating oil for patient | ||
| needle end | Medical grade silicone | Medical grade silicone |
| Lubricating oil for back | ||
| needle end | Medical grade silicone | Medical grade silicone |
8
6 Technological Characteristics:
The NovoFine® Plus needle is considered substantially equivalent to the predicate NovoFine® Plus disposable needle in intended use, technology, principles of operation, general type of materials and performance. Differences between the devices do not raise any significant issues of safety and effectiveness. For a detailed side by side comparison to the predicate needles cleared by the Agency, please see the table: Comparison to a legally marketed device in the substantial equivalence.
6.1 Non-Clinical Tests Performed:
The NovoFine® Plus needle will be manufactured in accordance with current Good Manufacturing Practices for Medical Devices. Biocompatibility and performance tests have been performed and the results are in compliance with existing domestic and international standards.
The clarification to the intended use of the subject pen needle device, does not introduce critical differences or new risks to the intended use of the device. The proposed clarification reflects current testing practice and aligns with compatibility summary provided in the submission. As part of the Quality System, NovoFine® Plus has been tested for functional compatibility according to ISO 11608-2:2012 with all leading pen injectors available on the market. This testing has shown connectivity to NovoFine® Plus and maintenance of the dose accuracy through the needle of all leading pen-injectors on the market covering different types of drugs. Thus, subject needle device meets requirements for its intended use and supports the proposed clarification.
List of all ISO standards used in non-clinical performance testing (sterility, biocompatibility, and performance):
- ISO 10993-1: 2018 Biological evaluation of medical devices-Part 1: Evaluation and testing within a risk management process.
- ISO 17665-1: 2006 Sterilization of health care products Moist heat-Part 1: Requirements ● for the development, validation and routine control of a sterilization process for medical devices
- ISO 11608-2: 2012 Needle-based injection systems for medical use Requirements and test ● methods -- Part 2: Needles
- ISO 9626: 2016 Stainless steel needle tubing for the manufacture of medical devices ●
Clinical Tests Performed: 6.2
No clinical tests are required.
6.3 Conclusion drawn from the non-clinical and clinical tests:
Based on the design equivalency and the functional testing, Novo Nordisk has determined that the NovoFine® Plus is substantially equivalent to predicate NovoFine Plus , K133738, which are currently marketed in the United States. Differences between the devices do not raise any significant issues of safety and effectiveness.